Top Markets
#1 Islamic Coin Islamic Coin +158.25%
#2 Glidr Glidr +58.56%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.53%
#4 Victoria VR Victoria VR +15.16%
#5 Cryptopia Cryptopia +9.09%
#6 Movement Movement +8.42%
#7 Pons Pons +7.64%
#8 DMT-NAT DMT-NAT +5.07%
#9 COTI COTI +5.06%
#10 MarsCoin MarsCoin +4.61%
Coin of the day
Islamic Coin Islamic Coin
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Sienna Biopharmaceuticals, Inc. Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals, Inc.

SNNAQ
Peringkat dalam Saham #42234
Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm... Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm dedicated to discovering and advancing pharmaceutical treatments across diverse therapeutic fields. Its primary focus involved crafting therapies within immunology and inflammation, specifically targeting particular tissue pathways, notably in the skin. Among its pipeline, SNA-120 stood out as a pioneering, first-in-class inhibitor of tropomyosin receptor kinase A, undergoing Phase IIb clinical evaluation for addressing psoriasis and its associated itching. Another key candidate, SNA-125, a topical dual Janus kinase 3 inhibitor, progressed through Phase I/II clinical studies for conditions like atopic dermatitis, psoriasis, and pruritus. Furthermore, Sienna was advancing SNA-001, a topical suspension incorporating silver particles, into pivotal clinical trials not only for acne treatment but also for diminishing light-colored hair, encompassing shades such as white, gray, blonde, light brown, and light red. Established in 2010 and based in Westlake Village, California, the company originally operated as Sienna Labs, Inc. before rebranding as Sienna Biopharmaceuticals, Inc. in February 2016. However, the firm faced significant financial challenges, initiating Chapter 11 bankruptcy proceedings on September 16, 2019, which subsequently converted to Chapter 7 liquidation on December 18, 2019.
Harga Saham
$0.0001
Terakhir disinkronkan: 2026-08-11
Kapitalisasi Pasar
$3.09K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Sienna Biopharmaceuticals, Inc. (SNNAQ)

Kategori

Healthcare
Margin Operasi untuk Sienna Biopharmaceuticals, Inc. (SNNAQ)
Margin Operasi per 2026 TTM: 0.00%
Menurut laporan keuangan dan harga saham terbaru dari Sienna Biopharmaceuticals, Inc., margin operasi saat ini (TTM) adalah 0.00%. Pada akhir 2026, margin operasi perusahaan adalah 0.00%.
Riwayat margin operasi untuk Sienna Biopharmaceuticals, Inc. dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Margin Operasi untuk perusahaan sejenis atau pesaing
Perusahaan Margin Operasi Perbedaan Margin Operasi Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.